Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib

PURPOSE: Fedratinib (INREBIC(®)), a Janus kinase 2 inhibitor, is approved in the United States to treat patients with myelofibrosis. Fedratinib is not only a substrate of cytochrome P450 (CYP) enzymes, but also exhibits complex auto-inhibition, time-dependent inhibition, or mixed inhibition/inductio...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Fan, Krishna, Gopal, Surapaneni, Sekhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515950/
https://www.ncbi.nlm.nih.gov/pubmed/32886148
http://dx.doi.org/10.1007/s00280-020-04131-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515950/
https://www.ncbi.nlm.nih.gov/pubmed/32886148
http://dx.doi.org/10.1007/s00280-020-04131-y

Ejemplares similares